Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 346 7764

Website: www.psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada

__AvengerTrader Dec. 4 at 11:42 PM

What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. Picked more $LIDR $PBM $PAPL $GCTK now

0 · Reply

ParabolicUptrends Dec. 4 at 8:52 PM

Micro float SNSE is getting a lot of attention! Could be the next crazy runner! Never chase those big runners that are up 100%+ .. Easy way to lose! Key is to buy early before the runs happen! 💎 These tiny float tickers are running 100-400% recently! SNSE starting to get discovered and trending on Stocktwits! Only 500k shares outstanding - keep it on watch bulls! $LASE $APVO $PBM $RAYA now

0 · Reply

picamjastor Dec. 4 at 11:19 AM

$PBM 1000 more watchers on stock twits in one month. This is ready to fly to 2.5$

0 · Reply

mcfaddenmn Dec. 4 at 1:41 AM

$PBM Psilocybin delays aging, extends lifespan, new Emory study suggests https://share.google/nt4PAyzymLlpdNgvL

0 · Reply

VolcanicTrades Dec. 3 at 9:53 PM

$PBM come on with it

0 · Reply

MyPreciousShares Dec. 3 at 9:35 PM

$PBM I missed this. It’s a big deal. Obviously if psilocybin reduces aging, it becomes the next Ozempic

1 · Reply

Peachtreegal Dec. 3 at 8:41 PM

$PBM

0 · Reply

RuddyRolls Dec. 3 at 7:34 PM

$PBM Ibogaine is the core treatment in this moving must see new Netflix doco. "A group of veterans who have found psychedelics immensely helpful in treating their PTSD and depression symptoms are the subject of a new Netflix documentary." https://time.com/7330333/in-waves-and-war-documentary-netflix/

0 · Reply

DaBullRunner Dec. 3 at 6:45 PM

$PBM pounded the table here in the $2’s DID YOU LISTEN??!!!!! Now I’m POUNDING the table on EPOW 🚨EPOW🚨just received a $30M contract AH This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰 $KITT $IBRT $VRAX $MCRP what a day

0 · Reply

DaBullRunner Dec. 3 at 6:41 PM

$PBM there it goes… 🚨EPOW🚨just received a $30M contract AH This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 14 days ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 22 days ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 4 weeks ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 4 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 5 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 6 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 6 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 6 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 6 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 7 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 8 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 8 months ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 8 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 8 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 8 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 9 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 9 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 10 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 19, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Sep 18, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 16, 2024, 9:31 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 13, 2024, 4:30 PM EDT - 1 year ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 6, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Jul 26, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

__AvengerTrader Dec. 4 at 11:42 PM

0 · Reply

ParabolicUptrends Dec. 4 at 8:52 PM

0 · Reply

picamjastor Dec. 4 at 11:19 AM

$PBM 1000 more watchers on stock twits in one month. This is ready to fly to 2.5$

0 · Reply

mcfaddenmn Dec. 4 at 1:41 AM

$PBM Psilocybin delays aging, extends lifespan, new Emory study suggests https://share.google/nt4PAyzymLlpdNgvL

0 · Reply

VolcanicTrades Dec. 3 at 9:53 PM

$PBM come on with it

0 · Reply

MyPreciousShares Dec. 3 at 9:35 PM

$PBM I missed this. It’s a big deal. Obviously if psilocybin reduces aging, it becomes the next Ozempic

1 · Reply

Peachtreegal Dec. 3 at 8:41 PM

$PBM

0 · Reply

RuddyRolls Dec. 3 at 7:34 PM

0 · Reply

DaBullRunner Dec. 3 at 6:45 PM

0 · Reply

DaBullRunner Dec. 3 at 6:41 PM

$PBM there it goes… 🚨EPOW🚨just received a $30M contract AH This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

Sauceg Dec. 3 at 6:10 PM

$PBM another rug pull? Scammers

0 · Reply

Jejetrader Dec. 3 at 5:50 PM

$PBM needs more volumn

0 · Reply

Gemba6 Dec. 3 at 4:32 PM

$PBM

0 · Reply

Bouge123 Dec. 2 at 12:27 PM

$FTEL will this run harder then $SMX $KZIA $PBM $BYND

0 · Reply

VolcanicTrades Dec. 1 at 10:30 PM

$PBM keep an on 👁️ Bottom setting up

0 · Reply

Parth1125 Dec. 1 at 9:22 PM

$PBM for sure going to cross 3 this week

1 · Reply

Peachtreegal Dec. 1 at 6:16 PM

$PBM 3 soon

0 · Reply

prismmarketview Dec. 1 at 5:41 PM

PRISM Mid-Day Movers: Pharmaceuticals and Healthcare Lead Today's Movement. Moleculin Biotech (NASDAQ: $MBRX) jumped over 2,100% to about $6.11 after a 1‑for‑25 reverse split, with volume above average but shares still below key moving averages, underscoring high volatility and ongoing losses. Psyence Biomedical (NASDAQ: $PBM) inched up about 3% to $1.58 on light volume and remains well under its 50‑ and 200‑day averages, reflecting cautious sentiment despite its psychedelic‑medicine pipeline. Other Notable Movers: New Found Gold Corp. ( $NFGC) up 18% NKGen Biotech ( $NKGN) up 16% Permex Petroleum ( $OILCF) down 30% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-healthcare-lead-todays-movement/

0 · Reply

Surferboysa Dec. 1 at 5:23 PM

$PBM massive team behind pbm!

0 · Reply

Peachtreegal Dec. 1 at 1:36 PM

$PBM FYI https://finance.yahoo.com/news/psyence-biomed-announces-groundbreaking-psilocybin-120000971.html

0 · Reply

Jpeel1972 Nov. 30 at 4:25 PM

$PBM interesting https://x.com/cernovich/status/1994901358315749614?s=46

1 · Reply

RuddyRolls Nov. 28 at 11:11 PM

$PBM Strong piece from Jody Aufrichtig, CEO, Psyence BioMed "Psilocybin is not simply a molecule that alters consciousness. It is a compound that influences inflammation, stress pathways, cellular resilience, neuroplasticity, and potentially the processes that underpin biological aging itself. The research – still early, but compelling – suggests that psilocybin may reduce oxidative stress, protect telomeres, enhance neural and mitochondrial function, and extend the lifespan of human cells. If this holds true across rigorous models, we may be looking at one of the most exciting biological discoveries of our time. This is why Psyence BioMed became the first publicly listed company to launch a dedicated psilocybin longevity research initiative. " https://psyencebiomed.com/opinion-the-future-of-human-longevity-will-be-transformational-and-nature-may-hold-the-key/#

0 · Reply

Market Cap	2.95M
Revenue (ttm)	0.00
Net Income (ttm)	1.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	201,900
Avg Vol	621,304
Day's Range	N/A - N/A
Shares Out	1.87M
Stochastic %K	85%
Beta	0.28
Analysts	Strong Buy
Price Target	N/A